Myocardial infarction and use of low-dose oral contraceptives: A pooled analysis of 2 US studies

• Published in: Circulation (New York, N.Y.) Vol. 98; no. 11; pp. 1058 - 1063
• Main Authors: SIDNEY, S, SISCOVICK, D. S, PETITTI, D. B, SCHWARTZ, S. M, QUESENBERRY, C. P, PSATY, B. M, RAGHUNATHAN, T. E, KELAGHAN, J, KOEPSELL, T. D
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 15-09-1998; American Heart Association, Inc
• Subjects: Adolescent; Adult; Biological and medical sciences; Cardiology. Vascular system; Contraceptives, Oral - administration & dosage; Contraceptives, Oral - adverse effects; Coronary Disease - epidemiology; Coronary heart disease; Female; Heart; Humans; Incidence; Medical sciences; Myocardial Infarction - epidemiology; Risk Factors; United States; North America; America; Human; Infarct; Low dose; Risk factor; Sex; Oral administration; Myocardium; Cardiovascular disease; Female; Contraceptive; Coronary heart disease; Myocardial disease
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/01.CIR.98.11.1058

Population-based case-control studies to assess the relationship of low-dose oral contraceptive (OC) use with myocardial infarction (MI) were performed at 2 sites in the United States (California and Washington state). The purpose of the present study was to estimate risk of MI in relation to use of low-dose OCs in a pooled analysis combining results from the 2 sites.
The study included as cases women aged 18 to 44 years with incident MI who had no prior history of ischemic heart disease or cerebrovascular disease. Women in the case and control groups were interviewed in person regarding OC use and cardiovascular risk factors. The analysis included 271 MI cases and 993 controls. Compared with noncurrent users, the adjusted pooled odds ratio for MI in current OC users was 0.94 (95% CI, 0.44, 2.20) after adjustment for major risk factors and sociodemographic factors. Compared with never users, the adjusted pooled odds ratio for MI was 0.56 (0.21, 1.49) in current OC users and 0.54 (0.31, 0.95) in past OC users. Among past OC users, duration and recency of use were unrelated to MI risk as was current hormone replacement therapy. There was no evidence of interaction between OC use and age, presence of cardiovascular risk factors (hypercholesterolemia, hypertension, diabetes), obesity, or smoking.
We conclude that low-dose OCs as used in these populations are safe with respect to risk of MI in women.